| Issue Date | Title | Author(s) |
| 2019 | Association of frequent amplification of chromosome 11q13 in esophageal squamous cell cancer with clinical benefit to immune check point blockade. | Wang, Feng; Ren, Chao; Zhao, Qi; Xu, Nong; Shen, Lin; Dai, Guanghai; Yuan, Xianglin; Chen, Ye; Yang, Shujun; Shi, Jianhua; Hu, Xichun; Lin, Xiaoyan; Zhang, Qingyuan; Feng, Jifeng; Ba, Yi; Liu, Yunpeng; Li, Wei; Shu, Yongqian; Wang, Fenghua; Xu, Rui-hua |
| 25-Oct-2022 | Bifunctional anti-PD-L1/TGF-beta RII agent SHR-1701 in advanced solid tumors: a dose-escalation, dose-expansion, and clinical-expansion phase 1 trial | Liu, Dan; Zhou, Jun; Wang, Yongsheng; Li, Mingjun; Jiang, Haiping; Liu, Yunpeng; Yin, Xianli; Ge, Minghua; Xiang, Xiaojun; Ying, Jieer; Huang, Jian; Zhang, Yan-qiao; Cheng, Ying; Huang, Zhigang; Yuan, Xianglin; Han, Weiqing; Yan, Dong; Wang, Xinshuai; Liu, Pan; Wang, Linna; Zhang, Xiaojing; Luo, Suxia; Liu, Tianshu; Shen, Lin |
| 2019 | Camrelizumab combined with capecitabine and oxaliplatin followed by camrelizumab and apatinib as first-line therapy for advanced or metastatic gastric or gastroesophageal junction cancer: Updated results from a multicenter, open label phase II trial. | Shen, Lin; Peng, Zhi; Zhang, Yan-Qiao; Wei, Jia; Wang, Feng; Ying, Jieer; Deng, Yanhong; Gu, Kangsheng; Cheng, Ying; Yuan, Xianglin; Xiao, Juxiang; Wang, Linna; Zou, Jianjun |
| 1-Jun-2021 | Camrelizumab Combined with Chemotherapy Followed by Camrelizumab plus Apatinib as First-line Therapy for Advanced Gastric or Gastroesophageal Junction | Peng, Zhi; Wei, Jia; Wang, Feng; Ying, Jieer; Deng, Yanhong; Gu, Kangsheng; Cheng, Ying; Yuan, Xianglin; Xiao, Juxiang; Tai, Yanfei; Wang, Linna; Zou, Jianjun; Zhang, Yanqiao; Shen, Lin |
| 31-Dec-2024 | The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of colorectal cancer, 2024 update | Wang, Feng; Chen, Gong; Zhang, Zhen; Yuan, Ying; Wang, Yi; Gao, Yuan-Hong; Sheng, Weiqi; Wang, Zixian; Li, Xinxiang; Yuan, Xianglin; Cai, Sanjun; Ren, Li; Liu, Yunpeng; Xu, Jianmin; Zhang, Yanqiao; Liang, Houjie; Wang, Xicheng; Zhou, Aiping; Ying, Jianming; Li, Guichao; Cai, Muyan; Ji, Gang; Li, Taiyuan; Wang, Jingyu; Hu, Hanguang; Nan, Kejun; Wang, Liuhong; Zhang, Suzhan; Li, Jin; Xu, Rui-Hua |
| 20-May-2020 | Clinical response and biomarker analysis of a phase II basket trial of toripalimab, a PD-1 mAb in combination with standard chemotherapy as a first-line treatment for patients with solid tumors. | Ren, Chao; Wei, Xiao-Li; Xu, Nong; Shen, Lin; Dai, Guanghai; Yuan, Xianglin; Chen, Ye; Yang, Shujun; Shi, Jianhua; Hu, Xichun; Lin, Xiaoyan; Zhang, Qingyuan; Feng, Jifeng; Ba, Yi; Liu, Yunpeng; Liu, Wei; Shu, Yongqian; Xu, Rui-hua; Junshi, Shanghai |
| 20-May-2020 | Clinical response and biomarker analysis of POLARIS-02 a phase II study of toripalimab, a humanized IgG4 mAb against programmed death-1 (PD-1) in patients with metastatic nasopharyngeal carcinoma. | Wang, Fenghua; Wei, Xiao-Li; Feng, Jifeng; Li, Qi; Xu, Nong; Hu, Xichun; Liao, Wangjun; Jiang, Yi; Lin, Xiaoyan; Zhang, Qingyuan; Yuan, Xianglin; Huang, Haixin; Chen, Ye; Dai, Guanghai; Shi, Jianhua; Shen, Lin; Yang, Shujun; Shu, Yongqian; Liu, Yunpeng; Xu, Rui-hua |
| Aug-2020 | National guidelines for diagnosis and treatment of colorectal cancer 2020 in China (English version) | Sun, Yan; Zheng, Shu; Wan, Desen; Gu, Jin; Wang, Jianping; Zhang, Suzhan; Cai, Sanjun; Fang, Xuedong; Fu, Chuangang; Jia, Baoqing; Kong, Dalu; Lan, Ping; Pan, Zhizhong; Pei, Haiping; Qiu, Huizhong; Song, Chun; Wang, Guiying; Wang, Xishan; Wang, Ziqiang; Xu, Jianmin; Xu, Zhongfa; Yan, Jin; Ye, Yingjiang; Yu, Yueming; Zhang, Zhongtao; Zhao, Ren; Lian, Lei; Liu, Qian; Peng, Yifan; Shen, Lin; Xu, Ruihua; Li, Jin; Ba, Yi; Bai, Chunmei; Bai, Li; Deng, Yanhong; Li, Jian; Liu, Tianshu; Liu, Yunpeng; Pan, Hongming; Tao, Min; Xu, Jianming; Yuan, Xianglin; Yuan, Ying; Zhang, Yanqiao; Zhou, Aiping; Wang, Feng; Wang, Xicheng; Li, Yexiong; Zhang, Zhen; Cai, Yong; Gao, Yuanhong; Jin, Jing; Li, Yongheng; Liu, Shixin; Wang, Renben; Wu, Junxin; Zhang, Hongyan; Zhu, Li; Zhu, Yuan; Tang, Yuan; Liang, Zhiyong; Jin, Mulan; Liang, Li; Qiu, Zhiqiang; Sheng, Weiqi; Sun, Baocun; Xue, Weicheng; Zhou, Weixun; Sun, Yingshi; Dong, Jiangning; Wang, Yi; Yu, Tao; Zhang, Xiaoyan; Zhou, Zhiyang; Sun, Ruijia; Wang, Juan; Sun, Ruijia; Tang, Yuan; Wang, Feng; Wang, Juan; Zhou, Weixun; Yang, Yong; Chen, Jiajia; Chen, Yongkang; Cheng, Yu; Han, Zihan; Huang, An; Huang, Dandan; Li, Xin; Li, Yukun; Shi, Jingyi; Shi, Mengyuan; Song, Can; Wang, Hanyang; Xu, Jingxuan |
| 10-May-2022 | Paclitaxel and cisplatin with or without cetuximab in metastatic esophageal squamous cell carcinoma: a randomized, multicenter phase II trial | Lu, Zhihao; Zhang, Yanqiao; Fan, Qingxia; Pan, Yueyin; Jiang, Da; Lu, Ping; Zhang, Jingdong; Yuan, Xianglin; Feng, Jifeng; Yang, Shujun; Yue, Wenbin; Zhao, Lin; Xu, Yunhua; Luo, Jinhua; Shen, Lin |
| 1-Jun-2022 | Preliminary results of raltitrexed in Chinese patients with metastatic colorectal cancer: A prospective, multicenter, real-world study. | Li, Jin; Qin, Shukui; Zhou, Ai-Ping; Zhang, Yanqiao; Yuan, Xianglin; Qin, Baoli; Zeng, Shan; Shen, Lin; Yuan, Ying; Zhu, Liangjun; Wang, Weibo; Zhang, Xianwen; Liang, Jun; Ye, Feng; Chen, Ping; Wang, Huaizhang; Yu, Zhengyan; Fang, Yong; Yue, Lu; Xiong, Jianping |
| 2017 | Recombinant humanised anti-PD-1 monoclonal antibody (JS001) treatment for patients with refractory or metastatic nasopharyngeal carcinoma: preliminary results of an open-label, phase 1b/2, clinical study | Xu, Ruihua; Wang, Fenghua; Li, Qi; Shi, Jianhua; Shen, Lin; Zhang, Qingyuan; Yuan, Xianglin; Jiang, Yi; Xu, Nong; Chen, Ye; Hu, Xichun; Lin, Xiaoyan; Yang, Shujun; Ren, Chao |
| 2018 | Recombinant humanized anti-PD-1 monoclonal antibody (JS001) as salvage treatment for advanced esophageal squamous cell carcinoma: Preliminary results of an open-label, multi-cohort, phase Ib/II clinical study | Xu, Rui-hua; Wang, Fenghua; Shi, Jianhua; Feng, Ji Feng; Shen, Lin; Yang, Shujun; Hu, Xi-Chun; Dai, Guanghai; Xu, Nong; Jiang, Yi; Yongqian, Shu; Zhang, Qingyuan; Chen, Ye; Yuan, Xianglin; Lin, Xiaoyan; Ba, Yi; Li, Qi; Li, Wei; Huang, Haixin; Yao, Sheng |
| 2018 | Recombinant humanized anti-PD-1 monoclonal antibody (JS001) as salvage treatment for advanced esophageal squamous cell carcinoma: Preliminary results of an open-label, multi-cohort, phase Ib/II clinical study | Xu, Rui-hua; Wang, Fenghua; Shi, Jianhua; Feng, Ji Feng; Shen, Lin; Yang, Shujun; Hu, Xi-Chun; Dai, Guanghai; Xu, Nong; Jiang, Yi; Yongqian, Shu; Zhang, Qingyuan; Chen, Ye; Yuan, Xianglin; Lin, Xiaoyan; Ba, Yi; Li, Qi; Li, Wei; Huang, Haixin; Yao, Sheng |
| 2018 | Recombinant humanized anti-PD-1 monoclonal antibody (JS001) as salvage treatment for advanced gastric adenocarcinoma: Preliminary results of an open-label, multi-cohort, phase Ib/II clinical study | Xu, Rui-hua; Wang, Fenghua; Xu, Nong; Shen, Lin; Dai, Guanghai; Yuan, Xianglin; Shi, Jianhua; Yang, Shujun; Feng, Ji Feng; Hu, Xi-Chun; Zhang, Qingyuan; Chen, Ye; Lin, Xiaoyan; Ba, Yi; Liu, Yunpeng; Jiang, Yi; Yongqian, Shu; Li, Qi; Li, Wei; Yao, Sheng |
| 2018 | Recombinant humanized anti-PD-1 monoclonal antibody (JS001) as salvage treatment for advanced gastric adenocarcinoma: Preliminary results of an open-label, multi-cohort, phase Ib/II clinical study | Xu, Rui-hua; Wang, Fenghua; Xu, Nong; Shen, Lin; Dai, Guanghai; Yuan, Xianglin; Shi, Jianhua; Yang, Shujun; Feng, Ji Feng; Hu, Xi-Chun; Zhang, Qingyuan; Chen, Ye; Lin, Xiaoyan; Ba, Yi; Liu, Yunpeng; Jiang, Yi; Yongqian, Shu; Li, Qi; Li, Wei; Yao, Sheng |
| 2019 | Recombinant humanized anti-PD-1 monoclonal antibody (JS001) in patients with refractory/metastatic nasopharyngeal carcinoma: Interim results of an open-label phase II clinical study. | Wang, Fenghua; Wei, Xiao-Li; Feng, Ji Feng; Li, Qi; Xu, Nong; Hu, Xi-Chun; Jiang, Yi; Liao, Wangjun; Zhang, Qingyuan; Yuan, Xianglin; Huang, Haixin; Chen, Ye; Dai, Guanghai; Shi, Jianhua; Shen, Lin; Yang, Shujun; Shu, Yongqian; Liu, Yunpeng; Xu, Rui-hua |
| Mar-2022 | Subgroup Analysis by Ki-67 and Baseline CgA of the Randomized, Placebo-Controlled Phase 3 Study of Surufatinib in Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors (SANET-p) | Yu, Xianjun; Xu, Jianming; Shen, Lin; Bai, Chunmei; Li, Jie; Zhou, Zhiwei; Li, Zhiping; Li, Enxiao; Yuan, Xianglin; Chi, Yihebali; Yin, Yongmei; Lou, Wenhui; Xu, Nong; Bai, Yuxian; Zhang, Tao; Xiu, Dianrong; Wang, Xiuwen; Guan, Sha; Fan, Songhua; Su, Weiguo |
| Nov-2020 | Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study | Xu, Jianming; Shen, Lin; Zhou, Zhiwei; Li, Jie; Bai, Chunmei; Chi, Yihebali; Li, Zhiping; Xu, Nong; Li, Enxiao; Liu, Tianshu; Bai, Yuxian; Yuan, Ying; Li, Xingya; Wang, Xiuwen; Chen, Jia; Ying, Jieer; Yu, Xianjun; Qin, Shukui; Yuan, Xianglin; Zhang, Tao; Deng, Yanhong; Xiu, Dianrong; Cheng, Ying; Tao, Min; Jia, Ru; Wang, Wei; Li, Jing; Fan, Songhua; Peng, Mengye; Su, Weiguo |
| Nov-2020 | Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study | Xu, Jianming; Shen, Lin; Bai, Chunmei; Wang, Wei; Li, Jie; Yu, Xianjun; Li, Zhiping; Li, Enxiao; Yuan, Xianglin; Chi, Yihebali; Yin, Yongmei; Lou, Wenhui; Xu, Nong; Bai, Yuxian; Zhang, Tao; Xiu, Dianrang; Wang, Xiuwen; Yuan, Ying; Chen, Jia; Qin, Shukui; Jia, Ru; Lu, Ming; Cheng, Yuejuan; Zhou, Zhiwei; Li, Jing; He, James; Su, Weiguo |
| 2019 | Tumor mutational burden identifies chemorefractory gastric cancer with overall survival advantage after receiving toripalimab, a PD-1 antibody. | Xu, Rui-Hua; Wang, Feng; Wei, Xiao-Li; Wang, Fenghua; Xu, Nong; Shen, Lin; Dai, Guanghai; Yuan, Xianglin; Chen, Ye; Yang, Shujun; Shi, Jianhua; Hu, Xi-Chun; Lin, Xiaoyan; Zhang, Qingyuan; Feng, Ji Feng; Ba, Yi; Liu, Yunpeng; Wu, Hai; Feng, Hui; Yao, Sheng |
